CoChat
Sign Up
Cited by 50Atrial Fibrillation Management and OutcomesGalectins and Cancer BiologyHeart Failure Treatment and Management

Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study

Open access
Fashanu, Oluwaseun E., Norby, Faye L., Aguilar, David, Ballantyne, Christie M., Hoogeveen, Ron C., Chen, Lin Y., Soliman, Elsayed Z., Alonso, Alvaro +1 more·2017·American Heart Journal
DOI 10.1016/j.ahj.2017.07.001PMC PMC5673118
Open this paper in CoChat — free account

Abstract

Background Galectin-3, a β-galactoside binding lectin involved in important regulatory roles in adhesion, inflammation, immunity, and fibrosis, may be relevant to atrial fibrillation (AF) etiology. Methods We included 8,436 participants free of AF at baseline (1996-1998) and with measures of plasma galectin-3 from the Atherosclerosis Risk in Communities study. We ascertained incident AF through 2013 from study visit electrocardiograms, hospitalizations, and death certificates. Multivariable Cox proportional hazards models, adjusted for AF risk factors plus incident heart failure (HF) and coronary heart disease (CHD), were used to estimate hazard ratios for the association between galectin-3 and incident AF. Results The mean age (SD) of participants was 62.6 (5.6) years, and the sample was comprised of 58.7% women and 21.2% blacks. During a median follow-up of 15.7 years, 1,185 incident cases of AF were observed. After adjusting for AF risk factors, participants with galectin-3 levels ≥90th percentile (19.5 ng/mL) had a significantly higher risk of incident AF when compared with the lowest quartile (4.4-11.9 ng/mL), with hazard ratios (95% CI) of 1.40 (1.04-1.89) for the 90th-<95th percentile and 1.51 (1.11-2.06) for the 95th-100th percentile. This association was attenuated and no longer statistically significant after accounting for incident CHD and HF as time-dependent variables. Conclusions Elevated plasma galectin-3 is associated with increased risk of incident AF. Galectin-3 may increase AF risk via pathways involving CHD and HF.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ahj.2017.07.001

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Elite athletes may present higher levels of profibrotic markers which have been associated with incident or recurrent AF in the general population, including galectin-3, ST2, miR-21, TIMP-1, CITP, and PICP.

    “Elite athletes may present higher levels of profibrotic markers which have been associated with incident or recurrent AF in the general population [66,67,68], including galectin-3 [69], the suppression of tumorigenicity 2 (ST2) [70], and microRNA-21 (miR-21) [71], as well as tissue inhibitors of metalloproteinase 1 (TIMP-1), C-terminal telopeptide of type I collagen (CITP), and procollagen type I”

    From Atrial Fibrillation in Elite Athletes: A Comprehensive Review of the Literature (2024) · cites this paper as [67]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 30 · Cited by 50

Research works printed but not linked: 27

  1. [1]Wadke R Atrial fibrillation Dis Mon 2013 59 67 73 23410667
  2. [2]Ball J Carrington MJ McMurray JJV Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century Int J Cardiol 2013 167 1807 1824 23380698
  3. [4]Colilla S Crow A Petkun W Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population Am J Cardiol 2013 112 1142 1147 23831166
  4. [5]Jalife J Mechanisms of persistent atrial fibrillation Curr Opin Cardiol 2014 29 20 27 24281345
  5. [6]de Boer RA Voors AA Muntendam P Galectin-3: a novel mediator of heart failure development and progression Eur J Heart Fail 2009 11 811 817 19648160
  6. [7]Schotten U Verheule S Kirchhof P Pathophysiological mechanisms of atrial fibrillation: a translational appraisal Physiol Rev 2011 91 265 325 21248168
  7. [8]Takemoto Y Ramirez RJ Yokokawa M Galectin-3 regulates atrial fibrillation remodeling and predicts catheter ablation outcomes JACC Basic Transl Sci 2016 1 143 154 27525318 PMC4979747
  8. [9]Sonmez O Ertem FU Vatankulu MA Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation Med Sci Monit 2014 20 463 470 24651058 PMC3965288
  9. [10]Kornej J Schmidl J Ueberham L Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation PloS One 2015 10 e0123574 25875595 PMC4398460
  10. [11]Clementy N Benhenda N Piver E Serum galectin-3 levels predict recurrences after ablation of atrial fibrillation Sci Rep 2016 6 34357 27677964 PMC5039646
  11. [12]van der Velde AR Meijers WC Ho JE Serial galectin-3 and future cardiovascular disease in the general population Heart 2016 102 1134 1141 27084804 PMC5226848
  12. [13]Christenson RH Duh S-H Wu AHB Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure Clin Biochem 2010 43 683 690 20153309
  13. [14]Djousse L Matsumoto C Petrone A Plasma galectin 3 and heart failure risk in the Physicians’ Health Study Eur J Heart Fail 2014 16 350 354 24464746 PMC4646068
  14. [15]Ho JE Yin X Levy D Galectin 3 and incident atrial fibrillation in the community Am Heart J 2014 167 729 734 e721 24766984 PMC4007212
  15. [16]de Boer RA Verweij N van Veldhuisen DJ A genome-wide association study of circulating galectin-3 PloS One 2012 7 e47385 23056639 PMC3467202
  16. [17]ARIC Investigators The Atherosclerosis Risk in Communities (ARIC) study: design and objectives Am J Epidemiol 1989 129 687 702 2646917
  17. [18]Alonso A Agarwal SK Soliman EZ Incidence of atrial fibrillation in whites and African- Americans: the Atherosclerosis Risk in Communities (ARIC) study Am Heart J 2009 158 111 117 19540400 PMC2720573
  18. [19]Norby FL Soliman EZ Chen LY Trajectories of cardiovascular risk factors and incidence of atrial fibrillation over a 25-year follow-up: The ARIC Study (Atherosclerosis Risk in Communities) Circulation 2016 134 599 610 27550968 PMC4999250
  19. [20]Whelton SP Roy P Astor BC Elevated high-sensitivity C-reactive protein as a risk marker of the attenuated relationship between serum cholesterol and cardiovascular events at older age. The ARIC Study Am J Epidemiol 2013 178 1076 1084 24026395 PMC3783092
  20. [21]Folsom AR Lutsey PL Astor BC Chronic kidney disease and venous thromboembolism: a prospective study Nephrol Dial Transplant 2010 25 3296 3301 20353958 PMC2948836
  21. [22]Folsom AR Nambi V Bell EJ Troponin T, NT-pro BNP, incidence of stroke: The Atherosclerosis Risk in Communities (ARIC) Study Stroke 2013 44 961 967 23471272 PMC3614093
  22. [23]Chambless LE Folsom AR Sharrett AR Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study J Clin Epidemiol 2003 56 880 890 14505774
  23. [24]Grove ML Yu B Cochran BJ Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium PloS One 2013 8 e68095 23874508 PMC3709915
  24. [25]Lippi G Cervellin G Sanchis-Gomar F Galectin-3 in atrial fibrillation: Simple bystander, player or both? Clin Biochem 2015 48 818 822 25952321
  25. [26]Nayor M Wang N Larson MG Circulating galectin-3 is associated with cardiometabolic disease in the community J Am Heart Assoc 2016 5 e002347 PMC4859357 26722123
  26. [27]Chen D Procter N Goh V New onset atrial fibrillation is associated with elevated galectin-3 levels Int J Cardiol 2016 223 48 49 27529590
  27. [28]Szadkowska I Wlazel RN Migala M The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty Cardiol J 2013 20 577 582 24338533

Authors
Fashanu, O. E., Norby, F. L., Aguilar, D., Ballantyne, C. M., Hoogeveen, R. C., Chen, L. Y., Soliman, E. Z., Alonso, A., & Folsom, A. R.
Affiliations
  • University of Minnesota (US)
  • Baylor College of Medicine (US)
  • Wake Forest University Health Sciences (US)
Corresponding author
Folsom, Aaron R.
ORCID
Venue
American Heart Journal
Publisher
Elsevier BV
Published
2017-10
Volume
192
Pages
19-25
ISSN
0002-8703 (ISSN-L)
DOI
10.1016/j.ahj.2017.07.001
PMC
PMC5673118
OpenAlex
W2730187323
Cited by
50
References
30
Citations by year
2026: 1 · 2025: 1 · 2024: 6 · 2023: 4 · 2022: 9 · 2021: 7 · 2020: 13 · 2019: 5 · 2018: 4
FWCI
4.66
Type
journal article
Language
en
Open access
Licence
Locations
  • American Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • American Heart Association (16EIA26410001)
  • Abbott Diagnostics
  • National Heart, Lung, and Blood Institute (HHSN268201 100012C, HHSN268201100007C, HHSN2682 01100008C, HH-SN-268201100006C, HHSN268201100011C, HHSN268201100005C, HHSN268201100010C, HHSN26820 1100009C)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Life Sciences › Immunology and Microbiology › Immunology › Galectins and Cancer Biology
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
galectin-3, atrial fibrillation, incident atrial fibrillation, plasma biomarkers, heart failure, coronary artery disease, atrial fibrillation risk factors, inflammation, fibrosis
MeSH terms
Atrial Fibrillation, Electrocardiography, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, United States, Biomarkers, Incidence, Risk Assessment, Galectin 3, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review